Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2A Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Varoglutamstat (PQ912) in Patients With Early Alzheimer's Disease With a Stage-Gate to Phase 2B (VIVA-MIND)

Trial Profile

A Phase 2A Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Varoglutamstat (PQ912) in Patients With Early Alzheimer's Disease With a Stage-Gate to Phase 2B (VIVA-MIND)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Varoglutamstat (Primary)
  • Indications Alzheimer's disease; Mild cognitive impairment
  • Focus Adverse reactions; Pharmacokinetics; Proof of concept; Therapeutic Use
  • Acronyms VIVA-MIND
  • Sponsors Vivoryon Therapeutics
  • Most Recent Events

    • 23 Oct 2023 According to a Vivoryon Therapeutics media release, the company is now recruiting participants into the second cohort with 21 sites open across the U.S.
    • 23 Oct 2023 According to a Vivoryon Therapeutics media release, the study's independent data safety monitoring board (DSMB) unanimously recommend that the VIVA-MIND study of varoglutamstat should proceed with a dose of 600mg twice daily (BID) through the remainder of Phases 2a and 2b.
    • 07 Sep 2023 According to a Vivoryon Therapeutics media release, in July 2023, company announced that the first cohort was fully randomized into the study.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top